Shield Therapeutics upbeat as Accrufer trial initiated in Japan
(Alliance News) - Shield Therapeutics PLC on Friday reported the commencement of a phase two Accrufer trial in Japan for the treatment of pulmonary arterial hypertension. Read More
| Price | 10.25p on 12-12-2025 at 08:03:05 |
|---|---|
| Change | 0.00p 0% |
| Buy | 10.50p |
| Sell | 10.00p |
| Last Trade: | Sell 980.00 at 10.20p |
| Day's Volume: | 980 |
| Last Close: | 10.25p |
| Open: | 10.25p |
| ISIN: | GB00BYV81293 |
| Day's Range | 10.25p - 10.25p |
| 52wk Range: | 2.20p - 12.35p |
| Market Capitalisation: | £108.83m |
| VWAP: | 10.20p |
| Shares in Issue: | 1.06b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 980 | 10.20p | Ordinary |
08:03:03 - 12-Dec-25 |
| Sell* | 50,000 | 10.20p | Ordinary |
16:28:29 - 11-Dec-25 |
| Sell* | 1,083 | 10.00p | Ordinary |
15:21:00 - 11-Dec-25 |
| Sell* | 52,000 | 10.00p | Ordinary |
15:16:26 - 11-Dec-25 |
| Sell* | 2,079 | 10.00p | Ordinary |
15:12:10 - 11-Dec-25 |
| Sell* | 743 | 10.2225p | Ordinary |
15:08:03 - 11-Dec-25 |
| Sell* | 9,743 | 10.2225p | Ordinary |
15:07:53 - 11-Dec-25 |
| Sell* | 14,285 | 10.24p | Ordinary |
15:00:59 - 11-Dec-25 |
| Sell* | 80,406 | 10.025p | Ordinary |
13:04:21 - 11-Dec-25 |
| Sell* | 39,901 | 10.025p | Ordinary |
12:59:54 - 11-Dec-25 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Dec 2025 7:00 am | RNS-R | Shield Wins Gold at Titan Branding Awards |
| 3rd Dec 2025 7:04 am | RNS | Amends Senior Secured Debt Financing |
| 14th Nov 2025 7:03 am | RNS | Initiation of a Phase II Clinical Trial in Japan |
| 11th Nov 2025 7:00 am | RNS | ACCRUFeR Pediatric PK Results to be Presented |
| 7th Nov 2025 7:03 am | RNS | ACCRUFeR receives Authorisation by Korean Ministry |
| 23rd Oct 2025 7:00 am | RNS | Q3 2025 Trading Update |
| 14th Oct 2025 3:01 pm | RNS | Grant of Share Options to Chief Executive Officer |
| 1st Oct 2025 8:00 am | RNS | Total Voting Rights |
| 1st Oct 2025 7:02 am | RNS | Positive efficacy and tolerance in pediatric trial |
| 15th Sep 2025 7:00 am | RNS | £1.5 million placing supporting growth of ACCRUFeR |